… Lung cancer is the leading cause of cancer deaths worldwide. Targeting the … small-cell lung
cancer (NSCLC) research, treatment, and patient outcome over the last few years. Erlotinib is …

… advanced non-small cell lung cancer. Here, we report safety and efficacy data from a
large, global, open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment). …

… efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), … erlotinib at 14 sites
(17 departments) in Ibaraki (Japan) between December 2007 and December 2010. The tumor …

… on 4068 concentration samples from 1047 patients receiving erlotinib as a single agent or in
… erlotinib exposure in non-small cell lung cancer patients treated with single-agent erlotinib. …

… Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell
lung cancer (… We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) …

… advanced pancreatic cancer. The oral administration and manageable toxicity of erlotinib,
along … : This review summarizes safety data from major clinical trials of erlotinib in patients with …

… Non-small cell lung cancer (NSCLC) is one of the leading causes of deaths from cancer …
inhibitors (TKIs) such as gefitinib and erlotinib have improved clinical outcomes in patients with …

… a distinct safety profile in this population compared with non-Asian patients. We report safety
and … , open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment study). …

… We argue that safety could not be considered an issue, leaving … clearly demonstrate that
gefitinib is as efficacious as erlotinib. … erlotinib and gefitinib indicates gefitinib's activity and safety …

… with non-small-cell lung cancer (NSCLC). An analysis of the phase IV POLARSTAR
surveillance study examined the safety and efficacy of erlotinib in elderly Japanese patients with …